Datta Shaishav, Fitzpatrick Aisling M, Haykal Siba
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Latner Thoracic Surgery Laboratories, University Health Network, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.
SAGE Open Med. 2021 Jul 21;9:20503121211034924. doi: 10.1177/20503121211034924. eCollection 2021.
Vascularized composite allotransplantation represents the final level of the reconstructive ladder, offering treatment options for severe tissue loss and functional deficiencies. Vascularized composite allotransplantation is particularly susceptible to ischemia-reperfusion injury and requires preservation techniques when subjected to extended storage times prior to transplantation. While static cold storage functions to reduce ischemic damage and is widely employed in clinical settings, there exists no consensus on the ideal preservation solution for vascularized composite allotransplantation. This review aims to highlight current clinical and experimental advances in preservation solution development and their critical role in attenuating ischemia-reperfusion injury in the context of vascularized composite allotransplantation.
血管化复合组织异体移植代表了重建阶梯的最终阶段，为严重组织缺损和功能缺陷提供了治疗选择。血管化复合组织异体移植特别容易受到缺血再灌注损伤，并且在移植前延长保存时间时需要保存技术。虽然静态冷藏有助于减少缺血损伤并在临床环境中广泛应用，但对于血管化复合组织异体移植的理想保存溶液尚无共识。本综述旨在强调保存溶液开发方面当前的临床和实验进展，以及它们在减轻血管化复合组织异体移植背景下的缺血再灌注损伤中的关键作用。
